TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens (Q39424506)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens |
scientific article |
Statements
1 reference
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens (English)
1 reference
Yuichi Hikichi
1 reference
Kohei Honda
1 reference
Kouki Hikami
1 reference
Hitoshi Miyashita
1 reference
Isao Kaieda
1 reference
Saomi Murai
1 reference
Noriko Uchiyama
1 reference
Maki Hasegawa
1 reference
Tomohiro Kawamoto
1 reference
Takashi Sato
1 reference
Takashi Ichikawa
1 reference
Sheldon Cao
1 reference
Zhe Nie
1 reference
Lilly Zhang
1 reference
Johnny Yang
1 reference
Keisuke Kuida
1 reference
Erik Kupperman
1 reference
21 December 2011
1 reference
1 reference
Identifiers
1 reference